ProMIS Neurosciences Brief: Says Top-line Data From First-in-human Phase 1a Clinical Trial of PMN310 as a Treatment for Alzheimer's Disease "On Track" for Mid-2024
ProMIS Neurosciences Brief: Says Top-line Data From First-in-human Phase 1a Clinical Trial of PMN310 as a Treatment for Alzheimer's Disease "On Track" for Mid-2024
ProMis 神经科学简报：称将于 2024 年中期进行的 PMN310 作为阿尔茨海默病治疗的首次人体 1a 期临床试验的主要数据 “步入正轨”
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册